Riker Lauren Bullaro, Vice President, Finance, subtracted 1,176 shares of Pacira BioSciences, Inc. (PCRX) from its portfolio at the rate of $44.14 per share valuing $51,909 on Nov 20. The insider left behind 10,464 shares of the company to its portfolio. Currently, the 1st Resistance Point for this stock is $46.74, with a 2nd Resistance Point sitting at $47.44. Meanwhile, this company’s stock has a 1st Support Level at $45.45 and a 2nd Support Level at $44.86. Before making a move on any particular stock, readers often pay close attention to support and resistance markers. The last reported price for shares of Pacira BioSciences, Inc. (PCRX) was $46.04. Pacira BioSciences, Inc. (PCRX) stock has gained $0.50, or 2.88%, in the past five days. In the last full month, these shares have gained $4.81, or 11.67%. In the past three months, this stock’s price has risen by $9.66, or 26.55%. This year-to-date, Pacira BioSciences, Inc. (PCRX) shares have gained $3.02, or 7.02%.
Analyzing price projection indicators is a helpful way to determine whether a potential stock buy is a wise choice for profits in the short term, medium term, and long term. For Pacira BioSciences, Inc. (PCRX) stock, 100% of short-term indicators suggest that these shares are a “ Buy .” Meanwhile, 50% of medium-term indicators point to this stock being a “ Buy .” Looking further ahead, 50% of long-term indicators suggest that this stock is a “ Buy .”
With 41,731 K shares outstanding, this company currently has a market capitalization of $1,926,720K. Pacira BioSciences, Inc. (PCRX) generates $337,280 K in annual sales, amounting to annual net income of -$470 K. This stock has generated a 1-Year Total Return of -5.31%, a 3-Year Total Return of 38.44%, and a 5-year Total Return of -49.32%. This stock’s 5-Year Dividend Growth is 0.00%. Its Annual Dividend Yield is 0.00%, and its Annual Dividend Rate is 0.00.
In the most recently-reported fiscal quarter, which ended in 09/19, Pacira BioSciences, Inc. (PCRX) reported earnings of $0.26 per share. Wall Street analysts, on average, were expecting the company to report earnings of $0.13 per share, representing a 0.13 difference and 100.00% surprise. In the previous quarter ending in 06/19, the reported earnings of $0.23 represented a 0.09 difference from the consensus estimate calling for $0.14 per share, which was a 64.29% surprise.
For the current fiscal quarter, which is set to end in 12/2019, the average earnings estimate is $0.19 per share. This estimate came from a total of 6 Wall Street Analysts. Of those market experts, the high estimate was $0.28 and the low estimate was $0.10. In the year-ago quarter, Pacira BioSciences, Inc. (PCRX) generated per-share earnings of $0.28. If the analysts are correct about the current quarter’s earnings, the growth will be -32.14%.
Turning our focus now to insider trading activity, there have been 10 purchases (81,448 shares in total) and 5 sale (95,624 shares in total) in the last 3 months. In the last 6 months, there have been 28 insider buys amounting to 204,035 shares and 22 insider sales amounting to 159,026 shares. In the past full year, 34 insider purchases were made (involving 233,245 shares) and 25 insider sell-offs equivalent to 189,063 shares.
Moving onto liquidity, Pacira BioSciences, Inc. (PCRX) has a Current Ratio of 7.88, a Quick Ratio of 7.08 and a Cash Ratio of 6.32. Looking at this company’s capital structure, its Total Debt to Total Equity is 90.57, its Total Debt to Total Capital is 47.53, and its Total Debt to Total Assets is now 42.20. Looking even further ahead into the future, its Long-Term Debt to Equity is 1.09 and its Long-Term Debt to Total Capital is 90.46.